Next 10 |
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and bu...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and ha...
2024-04-22 10:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-12 14:12:23 ET Summary Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activat...
2024-04-03 16:44:05 ET More on Immunome Immunome: An Oncology Powerhouse In The Making Immunome: Why It Has Doubled Over The Last Month Immunome down 1%, prices $200M equity Read the full article on Seeking Alpha For further details see: Immunome ...
2024-04-02 14:07:46 ET Summary IMNM has acquired an anti-ROR1 antibody-drug conjugate, and ADC platform technology, from Zentalis Pharmaceuticals. IMNM has also acquired AL102 and AL101 from Ayala Pharmaceuticals. AL102 is already in a phase 3 study, with results expected in Q1'25...
2024-04-01 09:00:06 ET David Nierengarten from Wedbush issued a price target of $33.00 for IMNM on 2024-04-01 07:59:00. The adjusted price target was set to $33.00. At the time of the announcement, IMNM was trading at $24.68. IMNM currently trades -20.38% versus its 52 w...
2024-03-28 17:07:10 ET More on Immunome Immunome: Why It Has Doubled Over The Last Month Immunome down 1%, prices $200M equity Immunome announces underwritten public offering of common stock Read the full article on Seeking Alpha For further details s...
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on...
News, Short Squeeze, Breakout and More Instantly...
Immunome Inc. Company Name:
IMNM Stock Symbol:
NASDAQ Market:
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and bu...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and ha...
2024-04-22 10:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...